Bookmark
Print
Recommend
  • Home
  • About PBS/IC
    • Overview
    • Nomenclature
    • Causes
    • Diagnosis
      • Overview
      • Diagnostic flow
      • NIDDK
      • Differential diagnosis
    • Management
    • Patients
      • Patient quotes
      • Case studies
    • COB Foundation Survey
      • Overview
      • Diagnosis
      • Symptoms
      • Quality of life
      • Economic impact
    • Clinical Phenotyping
      • Background to UPOINT
      • What is UPOINT
      • UPOINT research
    • References
  • Product information
    • Overview
    • Efficacy
      • Study 1
      • Study 2
    • Tolerability
    • Volume
    • Optimum dose of chondroitin sulfate
    • Budget impact
    • Mode of Action
    • Rationale for using chondroitin sulfate for PBS/IC
      • Importance of bladder GAG layer
      • Importance of chondroitin sulfate in bladder wall GAG layer
      • Dr Hurst Presentation video
    • How to administer Uracyst
    • Recommended treatment plan
    • References
  • Resources
  • KOL webcast
  • Prescribing information & adverse incident reporting
  • Request a call back

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Dr Nickel
Interview

Click here
to watch the
interview in full

MOA
Animation

Watch the
mode of action video now

           Email
           updates

Sign up today and receive regular website updates

Where am I: Product information > How to administer Uracyst

How to administer Uracyst

The suggested method of instillation for Uracyst is:

  • The patient should lie on their back.
  • Using standard technique, insert a lubricated urinary catheter (gauge 8 to 12) into the urinary bladder via the urethra
  • Lower the open end of the catheter so that all urine is drained from the bladder into a receptacle for disposal
  • Elevate the open end of the catheter, insert a sterile funnel, or sterile syringe with the plunger removed, and pour in Uracyst
  • Once Uracyst has been instilled, remove the catheter
  • Instruct the patient to hold Uracyst in the bladder for as long as possible, but for at least 30 minutes
  • The patient may be released immediately after instillation
Uracyst should not be administered to any patient with known hypersensitivity to the solution. As Uracyst does not contain any preservatives or antimicrobials, any unused portion should be discarded immediately after instillation.

Home | About PBS/IC | Product information | Resources | KOL webcast | Prescribing information & adverse incident reporting | Request a call back | Contact us | Privacy | Sitemap | Copyright